Direct economic value generated and distributed, including revenues, operating costs, employee compensation, donations and other community investments, retained earnings, and payments to capital

Consolidated income statement

Finance income and expense

Taxation

Employee costs and share option plans for employees

Performance summary

In the community

Coverage of the organization’s defined benefit plan obligations.

Post-retirement benefits

Development and impact of infrastructure investments and services provided primarily for public benefit through commercial, in-kind, or pro bono engagement.

AZ and the British Red Cross

AZ and AMREF

AZ and Axios

AZ and VSO

AZ and AmeriCares

AZ and IHP

Understanding and describing significant indirect economic impacts, including the extent of impacts.

Supporting economic development

Direct energy consumption by primary energy source.

Global warming (Emissions from energy use) *

Energy saved due to conservation and efficiency improvements.

Global warming (Emissions from energy use) *

Initiatives to reduce indirect energy consumption and reductions achieved.

Global warming (Emissions from energy use) *

Total water withdrawal by source

Biodiversity, land and water use *

Partially reported.
Whilst we report robust information on the amount of water we use at each major location, we do not currently gather data globally on the primary water sources affected. This issue is managed locally at each site and we will review whether this information can be collected and presented in a meaningful way at the global level.

Strategies, current actions, and future plans for managing impacts on biodiversity.

Biodiversity, land and water use *

Total direct and indirect greenhouse gas emissions by weight.

Global warming *

Other relevant indirect greenhouse gas emissions by weight

Global warming *

Initiatives to reduce greenhouse gas emissions and reductions achieved.

Global warming *

Emissions of ozone-depleting substances by weight.

Ozone depletion *

Total water discharge by quality and destination.

Emissions to air and water *

Partially reported.
AstraZeneca has a strong commitment to monitoring the discharge of substances from our activities (see PIE section). Whilst we monitor and report on aggregate effluent discharge volumes, we do not currently collate information across all our major sites on the destination of individual discharges. This is something we are likely to address as we continue our work to further develop our understanding of PiE issues and the most appropriate way to provide transparent and meaningful information to our stakeholders would form an important part of that exercise.

Total weight of waste by type and disposal method.

Waste management *

Initiatives to mitigate environmental impacts of products and services, and extent of impact mitigation.

Products and packaging *

Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with environmental laws and regulations.

SHE compliance

Significant environmental impacts of transporting products and other goods and materials used for the organization’s operations, and transporting members of the workforce.

Global warming (Emissions from Transport) *

Rates of injury, occupational diseases, lost days, and absenteeism, and total number of work-related fatalities by region.

Safety 

Health and wellbeing

Partially reported.
Our Safety Health & Environment (SHE) operations report globally on incidents of occupational illness, injuries and fatalities (see SHE section). At present we do not collect globally data relating to the number of lost days / absenteeism from causes. This is something we may develop as an additional indicator going forward.

Education, training, counseling, prevention, and risk-control programs in place to assist workforce members, their families, or community members regarding serious diseases.

Health and wellbeing

Percentage of employees receiving regular performance and career development reviews.

Monitoring performance

Partially reported.
This information was only available for our US operations. We are looking in to the possibility of extending this indicator to our global operations.

Composition of governance bodies and breakdown of employees per category according to gender, age group, minority group membership, and other indicators of diversity.

Monitoring performance

Business organisation
 
The Chief Executive Officer, Senior Executive Team and delegation of authority 

Partially reported.
Our new HR database is currently being rolled out across our global operations. At present, information is collected for approximately 60% of our global workforce. We will be considering means of categorizing our global workforce to enable comparison at different levels in the organization.

Ratio of basic salary of men to women by employee category.

Monitoring performance

Partially reported.
Our new HR database is currently being rolled out across our global operations. At present, information is collected for approximately 60% of our global workforce. We will be considering means of categorizing our global workforce to enable comparison at different levels in the organization.

Percentage and total number of significant investment agreements that include human rights clauses or that have undergone human rights screening.

Monitoring performance

Partially reported.
Our due diligence process includes an assessment of those CR and social issues relevant to our sector, such as patient safety, sales and marketing practices, employment practices and SHE governance. Therefore, we believe this indicator is only partially applicable to our operations.

Percentage of significant suppliers and contractors that have undergone screening on human rights and actions taken.

Monitoring performance

Partially reported.
We have documented extensively our commitment to ensuring a fair and balanced process for the planned restructuring that has taken place in AstraZeneca over the past year. This has included consultation with some of the external communities affected by business change. We have also reported on our community and health sponsorhip programmes. However, given the specific definition of this indicator to include the effects of 'entering, operating, and exiting' on communities we believe this indicator is only partially applicable to our operations.

Public policy positions and participation in public policy development and lobbying.

Access to medicines (Pricing)

Access to medicines (IP)

Access to medicines(Compulsory licensing)

Access to medicines (Right to health)

Engaging stakeholders (Governments and non-governmental organisations) 

Governance, management and measurement (Responsibilities and accountabilities)

Total number of legal actions for anti-competitive behavior, anti-trust, and monopoly practices and their outcomes.

Commitments and contingent liabilities

Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with laws and regulations.

Commitments and contingent liabilities

Life cycle stages in which health and safety impacts of products and services are assessed for improvement, and percentage of significant products and services categories subject to such procedures.

Patient safety

Type of product and service information required by procedures, and percentage of significant products and services subject to such information requirements.

Patient safety

Programs for adherence to laws, standards, and voluntary codes related to marketing communications, including advertising, promotion, and sponsorship.

Sales and marketing

Total number of incidents of non-compliance with regulations and voluntary codes concerning marketing communications, including advertising, promotion, and sponsorship, by type of outcomes.

Sales and marketing (Measuring performance)

Monetary value of significant fines for non-compliance with laws and regulations concerning the provision and use of products and services

Commitments and contingent liabilities